These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17953872)

  • 1. [Chemoprevention for breast cancers].
    Lanng C
    Ugeskr Laeger; 2007 Sep; 169(36):2975-6. PubMed ID: 17953872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of aromatase inhibitors on bone metabolism].
    Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
    Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
    Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
    Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14. Breast cancer prevention.
    Salih AK; Fentiman IS
    Int J Clin Pract; 2002 May; 56(4):267-71. PubMed ID: 12074209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention of breast cancer for women at high risk.
    Chan K; Morris GJ
    Semin Oncol; 2006 Dec; 33(6):642-6. PubMed ID: 17145342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer prevention: present and future.
    Salih AK; Fentiman IS
    Cancer Treat Rev; 2001 Oct; 27(5):261-73. PubMed ID: 11871862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence rates and correlates in long-term hormonal therapy.
    Dunn J; Gotay C
    Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma].
    Leung F; Terzibachian JJ; Govyadovskiy A; Bourtembourg A; Maillet R; Riethmuller D
    Gynecol Obstet Fertil; 2009 May; 37(5):447-51. PubMed ID: 19394886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
    Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer.
    Castrellon AB; Glück S
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.
    Dodwell D; Coombes G; Bliss JM; Kilburn LS; Johnston S;
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):321-4. PubMed ID: 18387790
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal therapy for breast cancer: focus on fulvestrant.
    Versea L; Rosenzweig M
    Clin J Oncol Nurs; 2003; 7(3):307-11. PubMed ID: 12793337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.